“Dr. Schwarz is always thorough and professional, and his technicians provide excellent, skilled support. Highly recommend this practice.”
Will I Need Eye Injections for Diabetic Macular Edema Forever?
How We Confirm and Track the Swelling
Accurate measurement is at the heart of every treatment decision. The imaging tools available today give us a precise, objective picture of what is happening inside your eye at every visit.
Two things happen at nearly every visit. First, a dilated eye exam allows your retina specialist to view the retina directly. Second, a scanner called optical coherence tomography, or OCT, takes detailed cross-section images of the retina and produces a thickness measurement for the center of your macula. That number, tracked from visit to visit, is the primary measure your doctor uses to guide treatment decisions.
Sometimes the OCT scan alone does not fully explain what is happening. A test called fluorescein angiography uses a dye injected into a vein in your arm to photograph the blood vessels in your retina and show exactly where fluid is leaking. This is most helpful when your doctor is considering laser treatment for a specific leaking area or needs to assess blood flow more closely.
A drier macula typically earns a longer gap between visits. Your doctor compares your current thickness measurement against your own recent history, not a universal target, and pairs it with your reading vision. If both remain steady, the interval between appointments lengthens. If fluid returns, the schedule tightens again. That back-and-forth adjustment is a normal and expected part of long-term management, and a single thicker scan rarely changes the overall plan.
What the Injections Are and What to Expect
Many patients feel anxious about injection treatment before they experience it. Understanding the procedure and the reasoning behind it makes the process much easier to navigate.
The medicine is placed directly into the vitreous, which is the clear gel that fills the inside of the eye, so it can act right where the leaking is occurring. Anti-VEGF medicines are effective for treating diabetic macular edema that involves the center of the macula and has caused vision loss. The medicine does not repair the damaged vessels. Instead, it quiets the leak signal for several weeks, allowing the macula to dry out and vision to stabilize or improve. When the drug wears off, the signal can return, which is why repeat doses are necessary for most patients.
Most patients find the experience far less uncomfortable than they anticipated. Your eye is numbed with anesthetic drops or gel, then cleaned with an antiseptic solution. A small instrument gently holds the eyelid open, and the injection itself takes only a second or two. Afterward, you may notice a gritty feeling, a small red patch on the white of the eye, and a few new floaters. These are expected and typically resolve within a day or two.
Treatment starts at its most intensive because a swollen macula needs several doses in a row before it dries out and holds steady. This front-loading commonly means injections roughly once a month for the first several months. The stretch that feels relentless in month three is usually the most demanding period you will experience, with the schedule thinning out considerably after that.
Most retina practices use a strategy called treat-and-extend. You receive a treatment at each visit, and if the macula stays dry, the next appointment is pushed out by a few weeks. If fluid returns, the interval is shortened again. With newer medicines like faricimab (Vabysmo), more than sixty out of every one hundred participants in two large phase 3 trials were on every-sixteen-week dosing by the end of two years using this approach. Fewer visits, same goal.
How Many Injections People Typically Need, Year by Year
One of the most important things to understand is that treatment intensity almost always decreases over time. The numbers below reflect real-world trial data, not a personal prediction, but they give a helpful sense of the typical arc.
In a major five-year randomized trial, participants received a median of thirteen to seventeen injections over the entire five-year period. By years four and five, more than half of participants in some groups received no injections at all during that year, while still maintaining most of the vision gains they had achieved. The typical pattern looks something like this:
- Year one: roughly six to eight injections
- Year two: roughly two to three injections
- Year three: roughly one to two injections
- Years four and five: roughly zero to one injection per year
These are averages, and your own count may be higher or lower depending on how your macula responds.
Two people with the same diagnosis can end up on very different schedules. Longer-standing diabetes, higher A1c levels, and stubborn swelling that is slow to dry tend to mean more doses. A macula that dries quickly and stays dry tends to mean fewer. Your doctor cannot predict precisely which pattern applies to you until treatment is well underway, usually after three to six months.
In some situations, the right number of injections right now is zero. In one clinical trial, eyes with center swelling but vision of 20/25 or better showed no meaningful difference in vision loss at two years whether they received immediate injections or were closely monitored with treatment started only if vision declined. This approach works only when follow-up visits happen reliably, because the goal is to catch any change quickly.
Discontinuing injections should always be a decision made with your retina specialist, not a personal choice after one good visit. Fluid that returns quietly between appointments can take vision with it before you notice anything is wrong. Research suggests that a longer unbroken period with a dry macula is associated with a better chance of successfully stopping treatment. The safer approach is to continue monitoring visits even when injections are paused or stopped.
Other Treatments That May Reduce Your Injection Burden
Anti-VEGF injections are the first-line treatment for most patients, but other options exist and may be used alongside them or when injections are not producing the desired result.
Steroid-based treatments address swelling through the inflammation pathway rather than the VEGF pathway. A dexamethasone intravitreal implant is biodegradable and releases medicine into the vitreous over a period of months. A fluocinolone acetonide implant (Iluvien) is designed as a sustained-release system intended to last up to thirty-six months. Both are approved in the United States for diabetic macular edema. Steroid implants carry a known risk of elevated eye pressure and cataract formation, so your doctor monitors eye pressure at follow-up visits. A cataract that develops can be treated surgically, so these are risks that are watched for and managed rather than ignored.
Laser treatment was the standard of care before anti-VEGF medicines became available and still plays a role today. Focal laser targets specific leaking spots in the retina rather than the entire macula. It is most useful when swelling sits away from the very center of vision and is sometimes used alongside injections to slow how frequently fluid returns.
Several anti-VEGF medicines are used for diabetic macular edema, including bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo). Bevacizumab was originally approved for cancer treatment given intravenously, so its use in the eye is off-label, meaning it is used in a way not listed on the official drug label. It costs considerably less, and many insurers require it as a first-line option before approving others. In one large trial, starting with bevacizumab and switching to aflibercept when needed produced vision outcomes within one to two letters of aflibercept alone at two years, though most patients in the bevacizumab-first group did end up switching. Your retina specialist can explain which medicines are available to you and what your insurance requires.
Surgery is a later-stage option, not a starting point. In a vitrectomy, the surgeon makes small openings in the eye wall and removes most of the vitreous gel. It is most often considered when scar tissue on the retina is physically pulling on the macula, a situation that no injection can resolve. Recovery is longer than with injection treatment, and vision outcomes are less predictable, which is why it is reserved for cases where other treatments have not been effective.
Warning Signs That Need Prompt Attention
Most injection days end without any serious problems, but knowing the difference between expected mild effects and signs of a real complication is important. Acting quickly on the right symptoms is what keeps a rare problem from becoming a lasting one.
Contact our office the same day if any of the following develop in the hours or days after an injection. If you cannot reach the office, go to an emergency room.
- Severe eye pain, or pain that keeps getting worse rather than better
- A red and painful eye, or new sensitivity to light
- Decreased vision, or a sudden shower of new floaters
These can be early signs of endophthalmitis, which is a serious infection inside the eye. The infection is uncommon, occurring roughly once in every two thousand or more injections in large studies, but it requires immediate treatment to protect vision. A scratchy or gritty eye for a day is expected. Pain that builds or vision that drops is not.
Outside of the injection setting, certain symptoms should also prompt a same-day call. A sudden drop in vision, a dark curtain appearing across part of your visual field, or a burst of new floaters with flashes of light can indicate a retinal tear, a retinal detachment, or bleeding inside the eye. Advanced diabetic retinopathy can pull the retina away from the back of the eye, which requires urgent attention. Eye clinics expect these calls and want to hear from you.
Some changes are not emergencies but should not wait for your next scheduled appointment. Call within a few days if your reading vision has slipped noticeably, straight lines look newly bent, a dull patch has appeared in the center of your vision, or you have a persistent ache that is not resolving. Also call ahead if you need to reschedule, because rescheduling protects your treatment interval in a way that simply dropping off the calendar does not.
What You Can Do Between Visits
The work of managing diabetic macular edema does not stop when you leave the clinic. Several things within your control have a meaningful effect on how the disease behaves over time.
In a landmark trial of people with type 1 diabetes, tight blood sugar control lowered the risk of developing retinopathy by about three quarters and slowed its worsening by about half in those who already had eye damage. High blood pressure and high cholesterol raise the risk of diabetic eye disease further. Better management of these factors will not empty your injection calendar overnight, but it changes the odds in your favor and supports the work the injections are doing.
A brief home vision check once a week can catch changes between clinic visits. Cover one eye and look at a straight edge such as a doorframe or an Amsler grid, which is a simple grid of straight lines used to detect distortion in central vision. Note whether lines look bent, wavy, or missing in any area, then repeat with the other eye. If something shifts from your own baseline, call the office rather than waiting for your next scheduled visit.
Practical planning makes a long-term schedule easier to sustain. Vision is often blurry for a few hours after dilation, so arranging a ride for the first few visits is wise until you know how you respond. Many patients book early-morning appointments and return to work the same day. If you work regular hours, asking your employer for a recurring appointment slot rather than explaining each absence individually tends to reduce friction over time.
Frequently Asked Questions
These are questions patients often have after the broader treatment process has been explained. Each answer is intended to help you apply what you have learned to your own situation.
Not necessarily right away, but that decision requires close monitoring rather than stepping back from care entirely. In eyes with center swelling and vision of 20/25 or better, careful observation with treatment started only if vision declined produced similar two-year outcomes to immediate injection. That result depends entirely on returning for scans as scheduled so treatment can begin the moment your vision is at risk. The danger is not skipping the injection. It is skipping the visit.
Do not assume the damage is permanent, and do not let embarrassment keep you away. Fluid commonly returns when treatment lapses, and some vision may slip with it. In many eyes, restarting treatment brings the swelling back down, though vision lost over a prolonged gap may not fully return. The most important step is to call and get back on the schedule. Letting your care team know what got in the way, whether cost, transportation, or something else, is also important because many barriers have practical solutions.
It genuinely supports the underlying disease, but treat it as a partner to injections rather than a replacement for them. No one can tell you in advance that improving your A1c will shorten your personal injection course, even though the science clearly shows it slows retinopathy overall. One important caution: lowering A1c very rapidly can temporarily worsen retinopathy, so significant changes to your diabetes regimen should be coordinated with both your diabetes care team and your retina specialist.
They are worth raising, especially if the frequency of visits is becoming a burden. Newer medicines in the anti-VEGF class are designed to maintain their effect over longer intervals, and in large clinical trials roughly eighty out of one hundred participants on a treat-and-extend schedule reached every-twelve-week or longer dosing by two years. Longer intervals are not guaranteed for every patient, and your insurance may require other medicines before covering newer options. Asking your retina specialist what interval they think your eye could safely tolerate is a reasonable and useful conversation.
Often yes, and treating both eyes in one visit can significantly reduce the total number of trips required over the course of treatment. When both eyes receive injections on the same day, separate sterile instruments and separate drug vials are used for each eye to prevent any problem from spreading from one eye to the other. Some doctors prefer to stagger the first few sessions to observe how you respond before committing to bilateral same-day treatment.
Yes, and this is the part of the plan that patients most commonly underestimate. Swelling can return without any noticeable symptoms at first, and catching that return on a scan is far better than catching it when your reading vision begins to slip. Monitoring visits continue even when injections become infrequent or stop entirely. The expectation over time is that the interval between appointments lengthens, not that appointments end.
Schedule a Visit With Our Team
At Atlantic Retina Center, our team of fellowship-trained, ABO board-certified retina specialists has dedicated their practice exclusively to the retina, vitreous, and macula, serving patients throughout the Eastern Shore of Maryland and central and southern Delaware. If you have been diagnosed with diabetic macular edema or have concerns about your retinal health, we are here to provide thorough evaluation and personalized care. We would welcome the opportunity to guide you through treatment with the expertise, honesty, and individual attention you deserve.